Navigating the FDA's 2026 Regulatory Framework for Cell and Gene Therapy
A practical guide for development teams and sponsors ready to move faster with confidence.
Executive Summary:
The FDA's 2026 CMC guidance represents a significant shift in how cell and gene therapies are developed and the data requirements for approval. For development teams and sponsors, understanding these changes is no longer optional — it is a strategic imperative.
A Practical Guide to the FDA's 2026 Regulatory Framework for Accelerating Cell and Gene Therapy Development by Keystone Biologics Advisory cuts through the complexity to deliver:
What has changed in the 2026 framework and why it matters
The accelerated pathways now available to CGT developers
Common regulatory missteps that delay approval — and how to avoid them
Practical strategies to align your development programme with FDA expectations
Whether you are early in development or approaching a regulatory submission, this guide gives you the clarity to move forward with precision.
Enter your name and email below to receive your complimentary copy.